Clinical trials: Advanced Solid Tumors, Adult
Solid Tumors, Lymphomas
Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas
The purpose of this trial is to explore the clinical utility of two investigational antibodies in patients with advanced cancer or lymphomas. This is a multi-center, open-label Phase I/Ib study.
- Trial name
- NCT02740270
- Testing
- GWN323, PDR001
- Where
- 9 sites in United States, Canada and 4 more
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor
A Study of ASP3082 in Adults With Advanced Solid Tumors
This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors…
- Trial name
- NCT05382559
- Testing
- Setidegrasib, Cetuximab, Leucovorin
- Where
- 68 sites in United States, China and 5 more
- Volunteers
- 681 people
- Sponsor
- Astellas Pharma Inc
Unspecified Adult Solid Tumor, Protocol Specific
VNP20009 in Treating Patients With Advanced Solid Tumors
RATIONALE: Biological therapies such as VNP20009 use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00006254
- Testing
- salmonella VNP20009
- Where
- 2 sites in United States
- Sponsor
- Vion Pharmaceuticals
Non-small Cell Lung Cancer, Colorectal Cancer
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
This is a Phase 1, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04121286
- Testing
- JAB-3312
- Where
- 5 sites in China
- Volunteers
- 17 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: SB939 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SB939 in treating patients with locally…
- Trial name
- NCT00504296
- Testing
- HDAC inhibitor SB939, immunoenzyme technique, immunohistochemistry staining method
- Where
- 2 sites in Canada
- Volunteers
- 39 people
- Sponsor
- NCIC Clinical Trials Group
Advanced Solid Tumor
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
To estimate the maximum tolerated dose (MTD) or recommended dose for phase II (RP2D) of CLR457 and to investigate the anti-tumor activity of CLR457
- Trial name
- NCT02189174
- Testing
- CLR457
- Where
- 7 sites in United States, Canada and 3 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumor, Soft Tissue Sarcoma Adult
Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors
This is a Phase 1, first-in-human, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 administered to patients with advanced solid tumors.
- Trial name
- NCT05352750
- Testing
- SON-1010
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Sonnet BioTherapeutics
Adult, Solid Tumor
LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors
RATIONALE: LY317615 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth and by stopping blood flow to the tumor.
- Trial name
- NCT00052273
- Testing
- capecitabine, enzastaurin hydrochloride
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of SJG-136 in treating patients with solid tumors that are metastatic or cannot be removed by surgery.
- Trial name
- NCT00121290
- Testing
- SJG-136, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma, Melanoma
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
This study will test the safety of a drug called PF-08046031 in participants with melanoma and other solid tumors that have no current approved treatment or have spread through the body.
- Conditions
- Malignant Melanoma, Melanoma, Metastatic Melanoma, Solid Tumors
- Trial name
- NCT06799533
- Testing
- PF-08046031
- Where
- 11 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Pfizer
Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer
A Study of VET3-TGI in Patients With Solid Tumors
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by…
- Conditions
- Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer
- Trial name
- STEALTH-001 (NCT06444815)
- Testing
- VET3-TGI, Atezolizumab
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- KaliVir Immunotherapeutics
Solid Tumor, Adult
PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor
In this single-center,open-label, phase I study, the safety and efficacy of PIN in combination with programmed cell death protein antibody (anti-PD1) therapeutic regimen will be evaluated in patients with late-stage advanced…
- Trial name
- NCT06883149
- Testing
- PIN +anti-PD1
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Chinese PLA General Hospital
Male Breast Cancer, Recurrent Bladder Cancer
Decitabine in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of decitabine in treating patients with advanced solid tumors that have not responded to previous treatment.
- Conditions
- Male Breast Cancer, Recurrent Bladder Cancer, Recurrent Breast Cancer, Recurrent Melanoma
- Trial name
- NCT00030615
- Testing
- decitabine, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00253565
- Testing
- capecitabine, imatinib mesylate
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Herbert Hurwitz
Advanced Cancer, Metastatic Cancer
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
- Conditions
- Advanced Cancer, Metastatic Cancer, Solid Tumor, Melanoma
- Trial name
- NCT05557045
- Testing
- JZP815
- Where
- 15 sites in United States
- Volunteers
- 98 people
- Sponsor
- Jazz Pharmaceuticals
Advanced Solid Tumors
Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001)
A study to evaluate safety and tolerability of MK6592 in combination with an anti-cancer drug in adult patients with advanced solid tumors.
- Trial name
- NCT00359671
- Testing
- MK6592, comparator: docetaxel
- Volunteers
- 38 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors
A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
Researchers are looking for a better way to treat advanced solid cancers including head and neck cancer, lung cancer and bladder cancer.
- Trial name
- NCT04999202
- Testing
- BAY2416964, Pembrolizumab
- Where
- 14 sites in United States, Italy and 2 more
- Volunteers
- 47 people
- Sponsor
- Bayer
Cancer, Advanced Solid Tumors
A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors
This is an open label, single arm, dose escalation study of ARQ 197 in patients with advanced solid tumors.
- Trial name
- ARQ 197 (NCT00612209)
- Testing
- ARQ 197
- Where
- United Kingdom
- Volunteers
- 51 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Solid Tumor, Adult
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
To determine the recommended phase 2 dose (RP2D) of the combination of neratinib and sodium valproate when given to patients with advanced solid tumors.
- Trial name
- NCT03919292
- Testing
- Neratinib, Divalproex Sodium
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Virginia Commonwealth University
Solid Tumor, Adult, Metastatic Solid Tumor
SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation
This is a Phase 1 study of BBP-398, a SHP2 inhibitor, in combination with sotorasib, a KRAS-G12C inhibitor (KRAS-G12Ci), in patients with a KRAS-G12C mutation.
- Conditions
- Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer
- Trial name
- Argonaut (NCT05480865)
- Testing
- BBP-398, sotorasib
- Where
- 25 sites in Australia, Denmark and 5 more
- Volunteers
- 28 people
- Sponsor
- Navire Pharma Inc., a BridgeBio company